SUGAR LAND--January 28, 2013--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--In the absence of the avalanche of mega-industry mergers and acquisitions (M&A) seen in previous years, many pundits have proclaimed the end of that particular business tool as an essential component in Big Pharma's playbook. While the numbers in 2012 of both quantity and value were less than in years past, it is apparent that M&A plans remain a key factor for the industry. With 2013 barely under way, rumors are in the air of new deals in the offing.
Other companies featured: Pfizer Incorporated (NYSE:PFE), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), GlaxoSmithKline (NYSE:GSK), Watson Pharmaceuticals Incorporated (NYSE:WPI), Allergan Incorporated (NYSE:AGN), MAP Pharmaceuticals (NASDAQ:MAPP)
All Members Receive the Following Free Resources:
Login using the form below or register for a free membership account using the form above.
Just Less than 400 U.S. Plants to Begin Operations in Second Half of 2013, ... U.S. Jobs Numbers Edge Up as Industrial Construction Starts Remain Strong i... INTERPHEX 2013: It's a Wrap on Pharma's Biggest Conference of the Year Got BIO? Better Get It! BIO 2013 Report Credits Industry with 1.6 Million H... BIO 2013 International Industry Conference Launches its 20th Year in the Wi...